Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1281110.RAbiw71LwldIQITqgCZhDqafKWvUY3J3UDRzYMOEe46IU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1281110.RAbiw71LwldIQITqgCZhDqafKWvUY3J3UDRzYMOEe46IU130_assertion type Assertion NP1281110.RAbiw71LwldIQITqgCZhDqafKWvUY3J3UDRzYMOEe46IU130_head.
- NP1281110.RAbiw71LwldIQITqgCZhDqafKWvUY3J3UDRzYMOEe46IU130_assertion description "[We retrospectively evaluated the efficacy and safety of high-dose erlotinib in EGFR-mutant non-small cell lung cancer (NSCLC) patients with refractory LM after failure of standard-dose EGFR-TKIs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1281110.RAbiw71LwldIQITqgCZhDqafKWvUY3J3UDRzYMOEe46IU130_provenance.
- NP1281110.RAbiw71LwldIQITqgCZhDqafKWvUY3J3UDRzYMOEe46IU130_assertion evidence source_evidence_literature NP1281110.RAbiw71LwldIQITqgCZhDqafKWvUY3J3UDRzYMOEe46IU130_provenance.
- NP1281110.RAbiw71LwldIQITqgCZhDqafKWvUY3J3UDRzYMOEe46IU130_assertion SIO_000772 25921002 NP1281110.RAbiw71LwldIQITqgCZhDqafKWvUY3J3UDRzYMOEe46IU130_provenance.
- NP1281110.RAbiw71LwldIQITqgCZhDqafKWvUY3J3UDRzYMOEe46IU130_assertion wasDerivedFrom befree-2016 NP1281110.RAbiw71LwldIQITqgCZhDqafKWvUY3J3UDRzYMOEe46IU130_provenance.
- NP1281110.RAbiw71LwldIQITqgCZhDqafKWvUY3J3UDRzYMOEe46IU130_assertion wasGeneratedBy ECO_0000203 NP1281110.RAbiw71LwldIQITqgCZhDqafKWvUY3J3UDRzYMOEe46IU130_provenance.